SCHEMBL9983385

SCHEMBL9983385

O=[N+]([O-])c1ccc(Cl)nc1Nc1ccc(N2CCCC(CO)C2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
LMNA P02545 3/20 0.39
BCL6 P41182 1/20 0.39
JAK2 O60674 1/20 0.38
SYK P43405 1/20 0.38
POLB P06746 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 3/20 0.37
CCR4 P51679 1/20 0.37
FGFR4 P22455 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.36
MEN1 O00255 1/20 0.36
THRB P10828 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
GAA P10253 1/20 0.36
HTT P42858 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
RET P07949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984036 0.88 HSF1 (0.44) MAPTLMNABCL6JAK2SYK
SCHEMBL9984401 0.87 MAPT (0.40) MAPTLMNABCL6JAK2SYK
SCHEMBL9984192 0.87 MAPT (0.41) MAPTLMNABCL6JAK2SYK
SCHEMBL9985270 0.87 MAPT (0.39) MAPTLMNABCL6JAK2SYK
SCHEMBL9983535 0.87 BRD4 (0.49) MAPTLMNABCL6JAK2SYK
SCHEMBL9984840 0.87 MAPT (0.41) MAPTLMNABCL6JAK2SYK
SCHEMBL9983529 0.86 FLT3 (0.42) MAPTLMNABCL6JAK2ALDH1A1
SCHEMBL9984359 0.86 MAPT (0.39) MAPTLMNABCL6JAK2SYK
SCHEMBL9984935 0.86 ATR (0.42) MAPTLMNAJAK2SYKALDH1A1
SCHEMBL9984049 0.85 MAPT (0.44) MAPTLMNAJAK2SYKPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 MAPT 4055/4885LMNA 2950/4885BCL6 4419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.